Aclarion Inc (ACON)vsMerck & Company Inc (MRK)
ACON
Aclarion Inc
$1.74
-1.14%
HEALTHCARE · Cap: $5.62M
MRK
Merck & Company Inc
$150.38
+3.93%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 80432036% more annual revenue ($67.38B vs $83,770). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 44/100 (D).
ACON
Avoid33
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACON.
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$150.38
$65.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 30.5% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.9x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 30.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ACON profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.21 — expect wider price swings.
ACON is growing revenue faster at 30.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is an innovative healthcare technology company focused on transforming the diagnosis and management of musculoskeletal conditions through advanced non-invasive imaging and data analytics. Leveraging machine learning capabilities, Aclarion provides healthcare professionals with actionable insights that improve clinical outcomes while optimizing cost-effective treatment pathways. As a key player in the digital health arena, the company is positioned to address the growing demand for effective diagnostic solutions, thereby enhancing patient care and management in a rapidly evolving healthcare environment. Aclarion's commitment to improving patient outcomes places it at the forefront of future healthcare delivery advancements.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?